A Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma who have been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

2019 ◽  
Vol 19 (10) ◽  
pp. e246
Author(s):  
Nizar J. Bahlis ◽  
Jeffrey A. Zonder ◽  
Susan Wroblewski ◽  
Ming Qi ◽  
Thomas Renaud ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Previously Treated ◽  
Randomized Phase 2

A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS8066-TPS8066 ◽  
Author(s):  
Jesus San Miguel ◽  
Marc S. Raab ◽  
Hartmut Goldschmidt ◽  
Sagar Lonial ◽  
Paul G. Richardson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Randomized Phase 2

scholarly journals Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

2016 ◽  
Vol 176 (5) ◽  
pp. 783-795 ◽  
Author(s):  
Noopur S. Raje ◽  
Philippe Moreau ◽  
Evangelos Terpos ◽  
Lotfi Benboubker ◽  
Norbert Grząśko ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Phase 2 ◽  
B Cell Activating Factor ◽  
Phase 2 Study ◽  
Previously Treated

scholarly journals Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Blood ◽  
2014 ◽  
Vol 123 (12) ◽  
pp. 1826-1832 ◽  
Author(s):  
Paul G. Richardson ◽  
David S. Siegel ◽  
Ravi Vij ◽  
Craig C. Hofmeister ◽  
Rachid Baz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Option ◽  
Low Dose ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Key Points ◽  
New Treatment ◽  
Randomized Phase 2

Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.

scholarly journals Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

Cancer ◽  
2012 ◽  
Vol 119 (2) ◽  
pp. 339-347 ◽  
Author(s):  
Darrell White ◽  
Adetola Kassim ◽  
Birbal Bhaskar ◽  
Jing Yi ◽  
Karen Wamstad ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document